PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study

Cisplatin-based chemotherapy is the standard treatment for bladder urothelial carcinoma (UC). Most patients experience chemoresistance, the primary cause of treatment failure, which leads to disease relapse. The underlying mechanism of chemoresistance involves reduced apoptosis. In this study, we in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Fu-Shun, Lin, Wei-Chou, Kuo, Kuan-Lin, Chiu, Yen-Ling, Hsu, Chen-Hsun, Liao, Shih-Ming, Dong, Jun-Ren, Liu, Shing-Hwa, Chang, Shih-Chen, Yang, Shao-Ping, Chen, Yueh-Tang, Chang, Ruei-Je, Huang, Kuo-How
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584183/
https://www.ncbi.nlm.nih.gov/pubmed/34769137
http://dx.doi.org/10.3390/ijms222111706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584183/
https://www.ncbi.nlm.nih.gov/pubmed/34769137
http://dx.doi.org/10.3390/ijms222111706

Ejemplares similares